MannKind Corporation stock rating and score history
All changes in ratings, performance and outlook tracked over time.
MannKind Corporation stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does MannKind Corporation do? Business model and key facts
Get the full picture of MannKind Corporation: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 592
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Stocks related to MannKind Corporation
Selected based on industry alignment and relative market positioning.
Events and news impacting MannKind Corporation stock
Earnings, coporate decisions and industry developments that can affect the share price.
MannKind Corporation fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
